Analysts Set Pediatrix Medical Group, Inc. (NYSE:MD) PT at $10.90

Pediatrix Medical Group, Inc. (NYSE:MD) has been given a consensus rating of “Hold” by the five brokerages that are currently covering the company, Marketbeat.com reports. Four analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $10.90.

A number of research analysts have recently issued reports on MD shares. Truist Financial boosted their price objective on Pediatrix Medical Group from $10.00 to $13.00 and gave the company a “hold” rating in a research note on Monday, October 7th. Jefferies Financial Group raised Pediatrix Medical Group from a “hold” rating to a “buy” rating and raised their price objective for the company from $8.00 to $14.00 in a research note on Thursday, September 26th. UBS Group upped their target price on Pediatrix Medical Group from $9.00 to $10.50 and gave the stock a “neutral” rating in a research report on Friday, August 9th. Finally, StockNews.com raised shares of Pediatrix Medical Group from a “sell” rating to a “hold” rating in a research report on Wednesday, August 7th.

Insiders Place Their Bets

In other news, CEO James D. Swift sold 11,100 shares of the firm’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $10.79, for a total transaction of $119,769.00. Following the sale, the chief executive officer now owns 170,001 shares in the company, valued at approximately $1,834,310.79. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other news, CFO C Marc Richards sold 32,562 shares of the firm’s stock in a transaction dated Friday, August 9th. The shares were sold at an average price of $10.08, for a total value of $328,224.96. Following the completion of the sale, the chief financial officer now directly owns 192,785 shares of the company’s stock, valued at approximately $1,943,272.80. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO James D. Swift sold 11,100 shares of Pediatrix Medical Group stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $10.79, for a total transaction of $119,769.00. Following the transaction, the chief executive officer now directly owns 170,001 shares of the company’s stock, valued at approximately $1,834,310.79. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 68,100 shares of company stock worth $701,889 in the last three months. 2.00% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of MD. Rubric Capital Management LP raised its holdings in Pediatrix Medical Group by 797.0% in the second quarter. Rubric Capital Management LP now owns 8,150,000 shares of the company’s stock worth $61,532,000 after buying an additional 7,241,400 shares during the last quarter. Dana Investment Advisors Inc. grew its position in Pediatrix Medical Group by 80.3% during the second quarter. Dana Investment Advisors Inc. now owns 1,023,136 shares of the company’s stock valued at $7,725,000 after buying an additional 455,785 shares during the period. Boston Partners boosted its position in shares of Pediatrix Medical Group by 34.0% in the first quarter. Boston Partners now owns 1,786,434 shares of the company’s stock worth $17,702,000 after purchasing an additional 453,254 shares during the period. Cubist Systematic Strategies LLC lifted its holdings in shares of Pediatrix Medical Group by 639.4% in the second quarter. Cubist Systematic Strategies LLC now owns 290,336 shares of the company’s stock worth $2,192,000 after buying an additional 251,072 shares in the last quarter. Finally, ClariVest Asset Management LLC purchased a new position in shares of Pediatrix Medical Group in the second quarter worth $1,721,000. 97.71% of the stock is owned by hedge funds and other institutional investors.

Pediatrix Medical Group Stock Down 2.7 %

Shares of NYSE:MD opened at $12.55 on Thursday. The company has a market capitalization of $1.06 billion, a price-to-earnings ratio of -14.76, a P/E/G ratio of 1.98 and a beta of 1.56. The company has a debt-to-equity ratio of 0.87, a current ratio of 1.38 and a quick ratio of 1.38. The business’s 50-day moving average is $11.31 and its 200-day moving average is $9.23. Pediatrix Medical Group has a 1 year low of $6.62 and a 1 year high of $12.99.

Pediatrix Medical Group (NYSE:MD) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $0.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.31 by $0.03. The company had revenue of $504.30 million for the quarter, compared to the consensus estimate of $505.49 million. Pediatrix Medical Group had a positive return on equity of 10.59% and a negative net margin of 12.58%. The firm’s revenue was up .7% compared to the same quarter last year. During the same period in the previous year, the business earned $0.37 EPS. Equities research analysts predict that Pediatrix Medical Group will post 1.19 earnings per share for the current year.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.